Epididymal cystadenomas and epithelial tumourlets: Effects of VHL deficiency on the human epididymis

Journal of Pathology

Volumn 210, Issue 1, 2006, Pages 32-41

  Glasker S ^a,b   Tran, M G B ^c   Shively, S B ^a,d   Ikejiri, B ^a   Lonser, R R ^a   Maxwell, P H ^c   Zhung, Z ^a   Oldfield, E H ^a   Vortmeyer, A O ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Epididymis cystadenoma; Hypoxia inducible factor; Tumour suppressor gene; von Hippel Lindau disease

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ARTICLE; AUTOPSY; CARCINOGENESIS; CLINICAL ARTICLE; CYSTADENOMA; DOWNSTREAM PROCESSING; EPIDIDYMIS DISEASE; EPITHELIUM TUMOR; GENE INACTIVATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; PRIORITY JOURNAL; UPREGULATION; VON HIPPEL LINDAU DISEASE; WILD TYPE;

CYSTADENOMA; EPIDIDYMIS; EPITHELIAL CELLS; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENITAL NEOPLASMS, MALE; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM PROTEINS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 33747876465     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2029     Document Type: Article

References (56)

1. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet 2003; 361(9374):2059-2067.
2. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260(5112):1317-1320.
3. Tory K, Brauch H, Linehan M, Barba D, Oldfield E, Filling-Katz M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989;81(14):1097-1101.
4. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfield EH, et al. Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997;28:(5): 540-543.
5. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90.
6. Zeiger MA, Zbar B, Keiser H, Linehan WM, Gnarra JR. Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer 1995;13(3):151-156.
7. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C, et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 2000;85(12):4568-4574.
8. Vortmeyer AO, Choo D, Pack SD, Oldfield E, Zhuang Z. von Hippel-Lindau disease gene alterations associated with endolymphatic sac tumor. J Natl Cancer Inst 1997;89(13):970-972.
9. Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. J Am Med Assoc 1997;277(18):1461-1466.
10. Vortmeyer AO, Lubensky IA, Fogt F, Linehan WM, Khettry U, Zhuang Z. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol 1997;151(4):951-956.
11. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997;94(6):2156-2161.
12. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cu12. Mot Cell Biol 1998;18(2):732-741.
13. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin -protein ligase activity. Genes Dev 1999;13(14):1822-1833.
14. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-275.
15. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275(33):25733-25741.
16. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2(7):423-427.
17. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Jr., Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93(20):10595-10599.
18. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF1α and HIF2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19(48):5435-5443.
19. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1(5):459-468.
20. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996;149(6):2089-2094.
21. Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, Oldfield EH. Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 2004;55(5):721-728.
22. Glasker S, Lonser RR, Tran MG, Ikejiri B, Butman JA, Zeng W, et al. Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res 2005;65(23):10847-10853.
23. Melmon KL, Rosen SW. Lindau's disease: review of literature and study of a large kindred. Am J Med 1964;36:595-617.
24. Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B, et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997;49(6):926-931.
25. Price EB Jr. Papillary cystadenoma of the epididymis. A clinicopathologic analysis of 20 cases. Arch Pathol Lab Med 1971;91(5):456-470.
26. Kragel PJ, Pestaner J, Travis WD, Linehan WM, Filling-Katz MR. Papillary cystadenoma of the epididymis. A report of three cases with lectin histochemistry. Arch Pathol Lab Med 1990;114(7):672-675.
27. Lissens P, Michiels H, Geysens P, Van de Voorde W, Lauweryns J. Papillary cystadenoma of the epididymis: a case report. Acta Urol Belg 1995;63(1):109-112.
28. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF1α and HIF2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157(2):411-421.
29. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187(2):620-626.
30. Zhuang Z, Vortmeyer AO. Applications of tissue microdissection in cancer genetics. Cell Vision 1998;5(1):43-48.
31. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation [see comments]. Cell 2001;107(1):43-54.
32. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003;3(1):75-88.
33. Vaux EC, Wood SM, Cockman ME, Nicholls LG, Yeates KM, Pugh CW, et al. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor. J Biol Chem 2001;276(47):44323-44330.
34. Wernert N, Goebbels R, Prediger L. Papillary cystadenoma of the epididymis. Case report and review of the literature. Pathol Res Pract 1986;181(2):260-264.
35. Brandt R. Zur Frage der Angiomatosis Retinae. von Graefes Arch Ophthalmol 1921.
36. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12(6):417-423.
37. Governale LS, Vortmeyer AO, Zhuang Z, Oldfield EH. Fibrous meningioma in a patient with von Hippel-Lindau disease: a genetic analysis. J Neurosurg 2001;95(6):1045-1049.
38. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol 1995;26(12):1341-1346.
39. Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, et al. Inactivation of von Hippel-Lindau gene induces constitutive phorphorylation of MET protein in clear cell renal carcinoma. Cancer Res 2006;66(7):3699-3705.
40. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, et al. Epigenetic inactivation of the RASSF1A 3p2l.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001;61(19):7277-7281.
41. Thompson GJ. Tumors of the spermatic cord, epididymis, and testicular tunics. Surg Gynec Obstet 1936.
42. Sherrick JC. Papillary cystadenoma of the epididymis. Cancer 1956;9(2):403-407.
43. Chan YH, Schinella RA, Draper JW. Papillary clear cell cystadenoma of the epididymis. J Urol 1968;100(5):661-665.
44. Grant ST, Hoffman EF. Bilateral papillary adenomas of the epididymis. Arch Pathol Lab Med 1963;76:620-625.
45. Meyer JS, Roth LM, Silverman JL. Papillary cystadenomas of the epididymis and spermatic cord. Cancer 1964;17:1241-1247.
46. Tsuda H, Fukushima S, Takahashi M, Hikosaka Y, Hayashi K. Familial bilateral papillary cystadenoma of the epididymis: report of three cases in siblings. Cancer 1976;37(4):1831-1839.
47. Calder CJ, Gregory J. Papillary cystadenoma of the epididymis: a report of two cases with an immunohistochemical study. Histopathology 1993;23(1):89-91.
48. Easton JA, Claridge M. Cystadenoma of the epididymis. Br J Urol 1964;36:416-417.
49. Hill RB, Bilateral papillary hyperplastic nodules of the epididymis. J Urol 1962;87:155-158.
50. Horster MF, Braun GS, Huber SM. Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev 1999;79(4):1157-1191.
51. Lindau A. Studien uber Kleinhirnzysten. Bau, Pathogenese und Beziehung zur Angiomatosis Retinae. Acta Path Microbiol Scand 1926; suppl 1:1-126.
52. Davison C, Brock S, Dyke CG. Retinal and central nervous system hemangioblastomatosis with visceral changes (von Hippel-Lindau's disease). Bull Neurol Inst NY 1936;5:72-93.
53. Tonning HO, Warren RF, Barrie HJ. Familial haemangiomata of cerebellum: report of three cases in a family of four. J Neurosurg 1952;9:124-132.
54. Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin A clinicopathologic study of 20 cases. Cancer 1989;64(11):2292-2302.
55. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota S, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF1) and HIF2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25(13):5675-5686.
56. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S, et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000;20:5454-5468.